Plus   Neg

Merck Says Phase 3 KEYTRUDA Trial Meets Primary Endpoint

Merck (MRK) Monday said its KEYTRUDA anti-PD-1 therapy for surgically resected high-risk melanoma met the primary endpoint of recurrence-free survival. The company, known as MSD outside the US, said phase 3 randomized, double-blind EORTC1325/KEYNOTE-054 trial resulted in significantly longer recurrence-free survival than placebo. The study will continue in order to evaluate other key endpoints, including overall survival.

Merck plans to present the results at an upcoming medical meeting.
In total, the study enrolled 1,019 patients who were randomly assigned to receive either KEYTRUDA at a flat dose of 200 mg intravenously on day 1 of each 21-day cycle for up to 1 year or placebo IV on day 1 of each 21-day cycle for up to 1 year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Opera, a web browser for Windows, macOS, and Linux operating systems, has added cryptocurrency mining protection to its mobile browsers. It is part of the browser's ad blocker function. In its desktop-based versions, Opera had introduced cryptocurrency miner protection in early January. French drug giant Sanofi SA Monday announced an agreement to buy US-based hemophilia drugmaker Bioverativ Inc. (BIVV) for around $11.6 billion. The deal expands Sanofi's presence in specialty care and strengthens leadership in rare diseases. Sanofi shares were losing around 4 percent in the early morning trading in Paris. Swiss banking giant UBS Group AG reported Monday a hefty net loss in its fourth quarter hurt by a charge related to US tax law changes. Pre-tax profit, however, increased from last year with improved operating income and lower expenses. Further, the company announced an increase in dividend, as well as a share buyback of up to 2 billion Swiss francs.
comments powered by Disqus
Follow RTT